BRCA突变携带者子宫内膜癌的发病率
研究前瞻性分析4959例无癌症史且子宫完整的BRCA突变携带者,平均随访6.7年,诊断38例子宫内膜癌(BRCA1携带者30例,BRCA2携带者8例),平均诊断年龄58.4岁。BRCA1携带者40至70岁累积发病率为3.4%,BRCA2为1.6%;既往他莫昔芬使用与风险显著增加两倍相关(HR=2.24;95%CI 1.10-4.55)。作者结论为年轻BRCA1突变携带者中子宫内膜癌发生率高于一般人群,但终生风险相似。
要点
- BRCA1携带者40至70岁子宫内膜癌累积发病率为3.4%,BRCA2携带者为1.6%。
- 既往他莫昔芬使用与子宫内膜癌风险显著增加两倍相关(HR=2.24;95%CI 1.10-4.55)。
- 外源性激素使用、卵巢切除术、吸烟或40岁时BMI与风险无显著关联(P≥0.32)。
核心结论
- 与一般人群相比,年轻BRCA1突变携带者中观察到子宫内膜癌发生率更高,但终生风险相似。
- 有既往他莫昔芬暴露的女性风险显著增加。
- 这些发现基于少量 incident 病例,需要对本衰老队列进行额外随访来确认。
研究设计与样本
- 前瞻性分析纳入4959例无既往癌症史(乳腺癌或黑色素瘤除外)且子宫完整的BRCA突变携带者。
主要发现
- 平均随访6.7年期间诊断38例子宫内膜癌,其中BRCA1携带者30例,BRCA2携带者8例。
- 诊断时平均年龄58.4岁(范围46.8-76.1)。
- 组织学亚型以子宫内膜样为主(n=16),其次为混合子宫内膜样和浆液性(n=4)、浆液性(n=3)或透明细胞(n=1),缺失13例。
- BRCA1携带者40至70岁累积发病率为3.4%,BRCA2突变携带者为1.6%。
- 既往他莫昔芬使用与显著增加两倍的风险相关(HR=2.24;95%CI 1.10-4.55)。
关键数值与推荐
- 既往他莫昔芬使用与子宫内膜癌风险相关(HR=2.24;95%CI 1.10-4.55)。
- 外源性激素使用、卵巢切除术、吸烟或40岁时BMI与风险无显著关联(P≥0.32)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现基于少量 incident 病例。
- 需要对本衰老队列进行额外随访来确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Whether or not women who harbor a germline pathogenic variant ('mutation') in the BRCA1 or BRCA2 genes are at elevated risk of developing endometrial cancer is yet to be determined. METHODS: We conducted a prospective analysis of 4959 BRCA mutation carriers with no prior history of cancer (except for breast or melanoma) and an intact uterus. RESULTS: After a mean of 6.7 years of follow-up there were 38 incident cases of endometrial cancer diagnosed; 30 among BRCA1 carriers and eight among BRCA2 carriers. The mean age at diagnosis was 58.4 years (range 46.8-76.1). The majority were of the endometrioid subtype (n = 16), followed by mixed endometroid and serous (n = 4), serous (n = 3) or clear cell (n = 1) (missing = 13). The cumulative incidence from age 40 to age 70 was 3.4% for BRCA1 carriers and was 1.6% for BRCA2 mutation carriers. Prior tamoxifen use was associated with a significant two-fold increased risk (HR = 2.24; 95% CI 1.10-4.55). There was no significant association between exogenous hormone use, oophorectomy, smoking or BMI at age 40 and risk (P ≥ 0.32). CONCLUSIONS: Compared to the general population, we observed higher rates of endometrial cancer among young BRCA1 mutation carriers; however, lifetime risks were similar. Women with prior tamoxifen exposure were at a significantly increased risk. These findings were based. on a small number of incident cases and require confirmation with additional follow-up of our aging cohort.
引用
- Kotsopoulos J, Lubinski J, Huzarski T, et al. Incidence of endometrial cancer in BRCA mutation carriers. Gynecol Oncol. 2024. PMID: 39173195. doi:10.1016/j.ygyno.2024.07.687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。